U.S., Oct. 4 -- ClinicalTrials.gov registry received information related to the study (NCT07205926) titled 'First in Human Dose Escalation Study Evaluating the Safety and Immunogenicity of IVT's Shigella-04 Vaccine in Healthy Young Adults' on Sept. 25.
Brief Summary: Phase 1 trial to evaluate the Safety and Immunogenicity of Inventprise's (IVT) Shigella-04 in Healthy Young Adults
Study Start Date: Oct. 09
Study Type: INTERVENTIONAL
Condition:
Shigella
Diarrhea
Intervention:
BIOLOGICAL: IVT Shigella-04
Preventative vaccine for Shigella protection against 4 unique serotypes
BIOLOGICAL: Placebo (0.9% saline)
Subjects dosed with 0.9% saline
Recruitment Status: RECRUITING
Sponsor: Inventprise Inc.
Published by HT Digital Content Ser...